Keyword : matching-adjusted indirect comparison
Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/−bevacizumab for the first-line treatment of non-squamous NSCLC: a matching-adjusted indirect comparison
|
|
|
|
|
Keyword : matching-adjusted indirect comparison |
|